FLT3 and acute myeloid leukemia: Among the various FLT3 inhibitors, midostaurin plus chemotherapy was approved by the FDA in 2017 for the treatment of adult patients with newly diagnosed FLT3-mutated AML and the FDA approved quizartinib plus chemotherapy to treat newly diagnosed AML patients with FLT3-ITD mutations last year [17, 18].